New studies indicate that taking Topamax (topiramate) during pregnancy increases the risk of cleft lip, cleft palate and/or genital birth defects in newborns. Further warnings indicate that Topamax can also be harmful to breastfeeding newborns. If your child has suffered from the effects of Topamax, a drug you understood to be safe to take during pregnancy or while breastfeeding, call our law offices today about filing a potential lawsuit or learn more about Topamax lawsuits now.
Topamax (topiramate) is a drug used to treat the following:
- Mood disorders
- Prevent migraines
- Chronic pain
In 2011, the FDA issued a warning to women of child-bearing age about the dangerous effects this drug can have on newborns. This came only after millions of children may have already been exposed. If your child is suffering due to Topamax, call Simmons Hanly Conroy. We can provide you with more information about possible Topamax lawsuits against the drug’s manufacturer Ortho MacNeil-Janssen Pharmaceuticals, Inc., and it’s parent company Johnson & Johnson.
In 2014, Simmons Hanly Conroy secured a $3 million verdict against Janssen Pharmaceuticals, awarded to the family of a 5-year-old child born with bilateral cleft palate and lip as a result of the mother taking Topamax during pregnancy.
“The result sends a clear message to the manufacturers of Topamax that failing to disclose the dangers associated with their medication is inexcusable,” said attorney Andy Williams of Simmons Hanly Conroy.
ABOUT TOPAMAX (TOPIRAMATE) SIDE EFFECTS
The Antiepileptic Drug Pregnancy Registry reports a 3.8 percent prevalence of oral birth defects in children exposed to Topamax in utero during the first trimester.
Two of the particular risks listed by this registry are cleft lip and/or cleft palate in newborns, which is known to develop in the first trimester of pregnancy before many women even know that they are pregnant.
Another defect common in Topamax lawsuits is a genital birth defect called hypospadias, found primarily in males, where the urethra opens on the underside of the penis.
It has also been noted that Topamax can pass into the newborn mother’s milk, which can, in turn, cause newborns to be exposed to trace amounts during breastfeeding.
Breastfeeding while taking Topamax can cause the following symptoms in newborns:
- Appetite loss
- Weight loss
If you believe your child may have been affected by Topamax, contact your physician immediately.
ADDITIONAL TOPAMAX LAWSUIT INFORMATION
The potential Topamax lawsuits of 2011 are separate from the Whistleblower lawsuits of March 2010 of which $81 million in settlements were paid out by Johnson & Johnson. These lawsuits and subsequent settlements were due to Johnson & Johnson’s illegal marketing of the drug for bipolar disorder, weight loss, alcohol abuse and other off-label uses that were not approved by the FDA.
ADDITIONAL INFORMATION ABOUT TOPAMAX
CONTACT SIMMONS HANLY CONROY FIRM
Simmons Hanly Conroy has represented thousands of clients harmed by dangerous drugs and recovered more than $260 million in verdicts and settlements* on their behalf. Our experienced pharmaceutical attorneys, led by named shareholders Paul Hanly and Jayne Conroy, are well-versed in handling complex medical and drug litigation involving Topamax, topiramate and other drugs that can cause birth defects.
Contact our experienced dangerous drug attorneys today to learn more about Topamax lawsuits and get a free legal consultation by calling 1-877-318-0580.
* Please note that recovery results vary per client. The recovery amounts in each case reflect the specific facts of that case. Further, recovery amounts in past cases are not a guarantee of future results.
- Simmons Hanly Conroy Investigates Birth Defects, Injuries Caused by Topamax
- Simmons Hanly Conroy secures $3 million verdict against Topamax manufacturer
I lost my wife to a heart attack caused by a dangerous drug. While nothing I do will ever bring her back, the Simmons firm helped ensure that other people won’t have to suffer the same loss as me. That product is no longer on the market and the companyRead More